Zomedica Pharma

123 articles about Zomedica Pharma

• Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024

  4/9/2024

  Zomedica Corp. announced that its Chief Executive Officer, Larry Heaton, will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Wednesday, April 17, 9:30 a.m. - 10:00 a.m. ET, on Track 2.

• Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity

  4/1/2024

  Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, reported consolidated financial results for the fourth quarter and year-ended December 31, 2023.

• Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET

  3/20/2024

  Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2023.

• Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform

  3/14/2024

  Zomedica Corp. announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave diagnostic platform to chemiluminescent immunoassay platforms currently broadly utilized by reference laboratories globally.

• Zomedica Provides NYSE American Listing Update

  3/13/2024

  Zomedica Corp. announced that it is continuing dialogue with senior regulatory staff at the NYSE American regarding next steps to regaining compliance with its listing standards.

• Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences

  3/12/2024

  Zomedica Corp. announced the presentation of veterinary education programs scheduled at the upcoming Fetch dvm360 Veterinary Conference and subsequent dvm360 Fetch programs.

• Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs

  3/7/2024

  Zomedica Corp. announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy.

• Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024

  3/5/2024

  Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place virtually on March 14th, 2024.

• Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET

  2/6/2024

  Zomedica Corp. announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET.

• Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split

  1/25/2024

  Zomedica Corp. announced that Institutional Shareholder Services, a leading independent proxy voting and corporate governance advisory firm, recommends that Zomedica Corp. shareholders vote "FOR" the proposed Share Consolidation/Reverse Stock Split detailed in the Company's definitive proxy statement filed on January 17, 2024.

• Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")

  1/17/2024

  Zomedica Corp. provided a business update and will be hosting a conference call.

• Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference

  11/28/2023

  Zomedica Corp. announced that the management team will be attending Noble Capital Markets' 19th Annual Emerging Growth Equity Conference at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida on December 5, 2023.

• Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies

  11/13/2023

  Zomedica Corp. reported consolidated financial results for the quarter ended September 30, 2023.

• Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET

  11/2/2023

  Zomedica Corp., a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its third quarter ended September 30, 2023.

• Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference

  10/10/2023

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

• Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development

  10/5/2023

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic devices for companion animals, announced the acquisition of Qorvo Biotechnologies LLC, creators of the OmniaTM and TRUFORMA® point of care diagnostic platforms.

• Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses

  9/14/2023

  Zomedica Corp. announced the commercial launch of its newest assay - endogenous ACTH for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform.

• Zomedica Provides Corporate Update - September 13, 2023

  9/13/2023

  Zomedica Corp. announced that, as disclosed in its Current Report on Form 8-K filed with the SEC on September 13, 2023, it has received formal notice from the NYSE American that it is not in compliance with the NYSE American's continued listing standard set forth in Section 1003 of the NYSE American Company Guide because the Company's common shares have been selling for a substantial period of time at a low price per share.

• Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio

  9/5/2023

  Zomedica Corp. announced it has completed the acquisition of Structured Monitoring Products, Inc., the makers of the VetGuardian™ touchless vital signs monitoring technology.

• Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity

  8/10/2023

  Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the quarter ended June 30, 2023.